Immunotherapies have greatly improved the treatment of metastatic melanoma, but they can cause serious side effects. A study led by researchers from Heidelberg University's Medical Faculty, the Heidelberg University Hospital, and the NCT in Heidelberg now shows that autoantibodies detected in the blood before the start of therapy could help to better assess the individual risk of side effects in patients.

Protein activity can be precisely regulated via subtle changes in temperature using heat-sensitive switches. Underlying this capability is a novel modular design strategy developed by researchers at the Institute of Pharmacy and Molecular Biotechnology of Heidelberg University. The strategy allows the integration of sensory domains in various proteins regardless of function or spatial structure.

New findings indicate that a shingles vaccination could not only reduce the risk of cognitive impairment and dementia, but also reduce disease progression among those living with dementia.

Artificial intelligence allows tracing the evolution of genetic control elements in the developing mammalian cerebellum. An international research team led by biologists from Heidelberg University as well as the Vlaams Instituut voor Biotechnologie and KU Leuven has now developed advanced AI models that can predict the activity of these elements based solely on their DNA sequence.

Scientists at the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD), and Mannheim University Medical Center (UMM) are presenting a method that enables artificial intelligence (AI) to learn how to transfer medical image data from animals to humans. This “xeno-learning” could help make surgical procedures safer and more precise in the future – without relying on human training data.

Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have developed a digital tool that significantly accelerates and improves clinical decisions in molecular precision oncology. The Knowledge Connector enables the structured and standardized evaluation of very extensive molecular tumor profiles and makes them available for personalized therapy decisions faster than before.

Tenderness can literally get under your skin: An international research group led by Heidelberg University's Medical Faculty and Heidelberg University Hospital has found that small skin wounds heal significantly faster in couples who are particularly affectionate with each other in everyday life and who also receive the hormone oxytocin. At the same time, they had lower stress levels.

Researchers at the Hopp Children's Cancer Center Heidelberg, the German Cancer Research Center, the Heidelberg Medical Faculty of Heidelberg University, and Heidelberg University Hospital have taken a decisive step toward more precise diagnosis of brain tumors. The latest version of the AI-based Heidelberg CNS Tumor Methylation Classifier can identify more than 180 tumor types —twice as many as the previous version.

Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital (UKHD) has received two awards for two independent research projects: his novel approach to preventing liver metastases and his research on T cells, which he modifies to better protect them from attacks by natural killer cells.

With victims numbering in the millions, malaria is an infectious disease caused by the bite of a mosquito carrying the malaria parasite. After penetrating the skin, the pathogen moves with helical trajectories. It almost always turns toward the right, as a team of physicists and malaria researchers from Heidelberg University recently discovered.

Heidelberg University has been successful in the current approval round of the German Research Foundation (DFG) with three grant applications for major research consortia. In the life sciences and medicine, a Collaborative Research Centre working on the Wnt signaling pathway will enter its third funding period. Two transregional consortia with major participation by researchers from Ruperto Carola have also been extended.

Sixteen leading life science and IT companies, all-new livestreamed presentations, and an informative career panel made for a successful EMBL Industry Day in its second year

In the PRECISION-ImmunoRad project, a multidisciplinary team of scientists from Heidelberg, USA, and Cyprus will unite their expertise to develop novel curative therapeutic strategies for currently hard-to-treat cancers. These strategies will integrate high-precision ion beam therapy with genetically engineered immune cells therapies (CAR-T cells), personalized cancer vaccines, and the targeted reprogramming of the tumor immune microenvironment.

Ependymomas, brain tumors that occur particularly in young children, are especially difficult to treat and more than half of the children affected have an increased risk of relapse. As part of an international consortium, the KiTZ, the DKFZ, the MFHD and UKHD have received a grant of 1.5 million pounds sterling (GBP) from the British organization The Brain Tumor Charity to develop a new type of immunotherapy for ependymoma.

Heidelberg researchers identify local outbreak indicators and develop new regional modeling approach. The highly pathogenic avian influenza virus infection – commonly known as bird flu – primarily affects birds. Mammals, however, are also increasingly infected. This increases the probability that the virus will cross over to humans.

On the basis of the cooperative relations that have developed over time, Heidelberg University and Harvard University are going to deepen and expand their cooperation. They have signed a Memorandum of Understanding to that effect. As an institutional internationalization project, the state of Baden-Württemberg is providing ten million euros to support this initiative, which is part of the state’s “Global Partnership in Science” activities.

Researchers at Heidelberg Uni Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human genome. A research team identified RNA:DNA hybrids as molecular signposts for the virus. These findings reveal a vulnerability in the life cycle of HIV and provide therapeutic approaches for specifically controlling HIV reservoirs in the body. This has been one of the obstacles to curative HIV therapies.

Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors.

A molecular mechanism that contributes to the progression of Alzheimer’s disease has been discovered by a research team of Heidelberg University. The team, using an Alzheimer’s mouse model, demonstrated that a neurotoxic protein-protein complex is responsible for nerve cells in the brain dying off and the resulting cognitive decline. This finding opens up new perspectives for the development of effective treatments.

Every brain tumor is made up of cells in successive stages of activation. Researchers have now analyzed the individual structure of these activation pyramids in malignant brain tumors. In doing so, they discovered a signaling protein that slows down the transition from a dormant to an activated state by epigenetically reprogramming the cells. The hope is that this will permanently freeze cancer cells in a dormant state and thus halt tumor growth.

The targeted engineering of artificial proteins with unique properties – that is possible with the assistance of a novel method developed by a research team of Heidelberg University. It centers around a new AI model. This allows for forecasting how two proteins have to be fitted together at the molecular level from individual parts – subunits – in order to engineer a functional, adjustable new protein.

FOXP1 syndrome is a congenital disorder in which the brain development of affected children is severely impaired due to a genetic variant. A research team from the Medical Faculty Heidelberg at Heidelberg University has now demonstrated in mice, that the inhibition of a specific enzyme in the brain can improve abnormal behavior and immune cell dysfunction in the brain. The results have been published in the journal Advanced Science.

Stem cell-like leukemia cells are responsible for relapses in children and adolescents with a certain type of blood cancer, T-ALL. Researchers at the Hopp Children's Cancer Center Heidelberg (KiTZ), the Molecular Medicine Partnership Unit and the German Cancer Research Center were able to show this in a study. The results could help to overcome resistance in this form of blood cancer and prevent relapses.

Sarcomas in soft tissue usually occur in young people and are difficult to treat. Due to a lack of laboratory models, the causes of their development are poorly understood. A team of researchers has now succeeded in creating mouse models with a functioning immune system that replicate sarcoma types that remain unstudied. The method opens up new avenues for the targeted development of immunotherapies for children and adolescents with sarcomas.

Dr Dr Varun Venkataramani and Dr Moritz Mall have been awarded this year’s Hella Bühler Prize for their outstanding research on the interaction between nerve and tumor cells and on tumor plasticity. The award granted by Heidelberg University goes to young researchers from the Heidelberg research location who have already drawn attention to themselves through the outstanding scientific quality of their cancer research.